Shanghai Junshi Biosciences Co., Ltd. (SHJBF)
USD 1.97
(51.54%)
USD 1.97
(51.54%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 4.02 Billion CNY | 44.58% |
| 2022 | 2.78 Billion CNY | 2.34% |
| 2021 | 2.71 Billion CNY | 25.3% |
| 2020 | 2.16 Billion CNY | 51.31% |
| 2019 | 1.43 Billion CNY | 53.17% |
| 2018 | 936.17 Million CNY | 832.68% |
| 2017 | 100.37 Million CNY | 347.8% |
| 2016 | 22.41 Million CNY | 58.27% |
| 2015 | 14.16 Million CNY | 8.34% |
| 2014 | 13.07 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 651.78 Million USD | 4.21% |
| 2024 Q2 | 4.38 Billion CNY | -12.43% |
| 2024 Q1 | 692.47 Million USD | 30.61% |
| 2023 Q4 | 541.12 Million USD | 21.66% |
| 2023 FY | 4.02 Billion CNY | 44.58% |
| 2023 Q1 | 415.56 Million USD | -85.06% |
| 2023 Q2 | 2.99 Billion CNY | 620.46% |
| 2023 Q3 | 444.79 Million USD | -85.14% |
| 2022 Q1 | 2.65 Billion USD | -2.46% |
| 2022 Q3 | 377.34 Million USD | -83.99% |
| 2022 Q4 | 2.78 Billion CNY | 637.26% |
| 2022 FY | 2.78 Billion CNY | 2.34% |
| 2022 Q2 | 2.35 Billion CNY | -11.12% |
| 2021 Q2 | 1.98 Billion CNY | -13.55% |
| 2021 FY | 2.71 Billion CNY | 25.3% |
| 2021 Q4 | 2.71 Billion CNY | 43.21% |
| 2021 Q3 | 1.89 Billion USD | -4.28% |
| 2021 Q1 | 2.29 Billion USD | 5.73% |
| 2020 Q4 | 2.16 Billion CNY | 22.06% |
| 2020 FY | 2.16 Billion CNY | 51.31% |
| 2020 Q3 | 1.77 Billion CNY | -17.98% |
| 2020 Q2 | 2.16 Billion CNY | 0.0% |
| 2020 Q1 | - CNY | -100.0% |
| 2019 Q4 | 1.43 Billion CNY | 0.0% |
| 2019 Q1 | 1.12 Billion CNY | 19.82% |
| 2019 FY | 1.43 Billion CNY | 53.17% |
| 2019 Q2 | 1.2 Billion CNY | 7.84% |
| 2018 Q2 | 384.26 Million CNY | 0.0% |
| 2018 Q1 | - CNY | -100.0% |
| 2018 FY | 936.17 Million CNY | 832.68% |
| 2018 Q4 | 936.17 Million CNY | 98.35% |
| 2018 Q3 | 471.98 Million CNY | 22.83% |
| 2017 Q2 | 19.03 Million CNY | 0.0% |
| 2017 Q4 | 100.37 Million CNY | 0.0% |
| 2017 FY | 100.37 Million CNY | 347.8% |
| 2017 Q1 | 19.03 Million CNY | 0.4% |
| 2016 FY | 22.41 Million CNY | 58.27% |
| 2016 Q2 | 4.64 Million CNY | 0.0% |
| 2016 Q1 | 4.64 Million CNY | -67.21% |
| 2016 Q4 | 18.96 Million CNY | 0.0% |
| 2016 Q3 | 18.96 Million CNY | 308.35% |
| 2015 Q1 | 20.72 Million CNY | 58.58% |
| 2015 FY | 14.16 Million CNY | 8.34% |
| 2015 Q3 | 14.16 Million CNY | -31.68% |
| 2015 Q4 | 14.16 Million CNY | 0.0% |
| 2015 Q2 | 20.72 Million CNY | 0.0% |
| 2014 Q4 | 13.07 Million CNY | 0.0% |
| 2014 FY | 13.07 Million CNY | 0.0% |
| 2014 Q3 | 13.07 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 50.26 Million USD | -7902.26% |
| Skye Bioscience, Inc. | 14.07 Million USD | -28482.935% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -6715.76% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -497215.262% |
| Qrons Inc. | 1.48 Million USD | -270083.44% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | -25189.784% |
| CSL Limited | 18.62 Billion USD | 78.399% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -5450.159% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -42391.967% |
| Regen BioPharma, Inc. | 5.45 Million USD | -73599.872% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -5268.735% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -8999040.863% |
| Rebus Holdings, Inc. | 5.24 Million USD | -76631.324% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -14662007.681% |
| Neon Bloom, Inc. | 1.22 Million USD | -327922.619% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -1999868.178% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -7445.739% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -41877.111% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -954017.96% |
| SQZ Biotechnologies Company | 50.03 Million USD | -7938.242% |
| Intellipharmaceutics International Inc. | 12 Million USD | -33394.33% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -104335.554% |
| Mesoblast Limited | 188.44 Million USD | -2034.45% |
| Marizyme, Inc. | 26.67 Million USD | -14978.346% |
| Genus plc | 485 Million USD | -729.331% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -68743.35% |
| Pharming Group N.V. | 244.07 Million USD | -1547.973% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -199999.297% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -159746.252% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -105748.842% |
| ContraFect Corporation | 32.53 Million USD | -12264.379% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -202910.133% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -104984.271% |
| IMV Inc. | 37.93 Million USD | -10503.638% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -34050.02% |
| MultiCell Technologies, Inc. | 1617.67 USD | -248644926.489% |
| ONE Bio Corp. | 27.49 Million USD | -14528.614% |
| Accustem Sciences Inc. | 1.07 Million USD | -372593.722% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -5095.572% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -190071.384% |
| Q BioMed Inc. | 8.13 Million USD | -49356.365% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -4749.89% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -78062.236% |
| Biomind Labs Inc. | 1.49 Million USD | -268298.758% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -3287.956% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -44383.186% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -21756.031% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -280419.241% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -2830580.883% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -69903.155% |
| GB Sciences, Inc. | 5.41 Million USD | -74144.83% |
| Alpha Cognition Inc. | 7.16 Million USD | -56039.328% |
| HST Global, Inc. | 593.59 Thousand USD | -677511.764% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -319331.255% |
| Halberd Corporation | 728.71 Thousand USD | -551862.553% |
| Enzolytics Inc. | 365.26 Million USD | -1001.176% |
| Agentix Corp. | 2.51 Million USD | -160113.817% |
| Resverlogix Corp. | 67.39 Million USD | -5868.093% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -479463.913% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | -803.977% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -234570.712% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -16154.149% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -33691.665% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -109642.866% |
| AVAX Technologies, Inc. | 3.99 Million USD | -100613.891% |
| Zenith Capital Corp. | 27.56 Thousand USD | -14589678.374% |
| Genscript Biotech Corporation | 1.32 Billion USD | -203.367% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -1685292.241% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -107610.937% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -590683.657% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -148232.91% |
| Kadimastem Ltd | 3.5 Million USD | -114662.015% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -6009635.69% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -865461.579% |
| LadRx Corporation | 2.2 Million USD | -182685.95% |
| Cell Source, Inc. | 15.8 Million USD | -25346.503% |
| Regen BioPharma, Inc. | 5.45 Million USD | -73599.872% |
| NovAccess Global Inc. | 7.86 Million USD | -51068.975% |
| Affymax, Inc. | 8.87 Million USD | -45241.63% |
| Itoco Inc. | 1.65 Million USD | -243208.446% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -195957.936% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -66394.561% |
| Mobile Lads Corp. | 1.31 Million USD | -306124.986% |
| CytoDyn Inc. | 127.89 Million USD | -3044.992% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -9622752.221% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -256687.223% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -36316.032% |
| SYBLEU INC | 681.41 Thousand USD | -590181.665% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -65818.037% |
| International Stem Cell Corporation | 5.27 Million USD | -76122.399% |
| Bioxytran, Inc. | 3.24 Million USD | -123680.766% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -642629.012% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -87016.03% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -9711.338% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -17965.376% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -198491.973% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -73325.63% |
| Neutra Corp. | 973.52 Thousand USD | -413062.422% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -13762.678% |
| PureTech Health plc | 125.58 Million USD | -3102.867% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -106956.752% |
| IXICO plc | 1.9 Million USD | -211565.155% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -19493.044% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -3792.857% |
| CSL Limited | 18.62 Billion USD | 78.399% |
| Cellectis S.A. | 249.36 Million USD | -1512.971% |